Skip to main content

Table 2 Median (IQR) costs in USD, by type of provider in first visit, incurred by patients with drug-susceptible pulmonary TB on treatment during January–June 2019, in Bhavnagar (n = 458)

From: Costs incurred by patients with drug-susceptible pulmonary tuberculosis in semi-urban and rural settings of Western India

Categories of costs

Total (n = 458)

Median (IQR)

Private provider (n = 60)

Median (IQR)

Government provider (n = 398)

Median (IQR)

P-value

Direct medical

0 (0–0)

30 (10–76)

0 (0–0)

<  0.001

 Day charges

0 (0–0)

3 (0–7)

0 (0–0)

<  0.001

 Consultation

0 (0–0)

0 (0–0)

0 (0–0)

<  0.001

 Radiography

0 (0–0)

4 (0–7)

0 (0–0)

<  0.001

 Laboratory

0 (0–0)

4 (0–7)

0 (0–0)

<  0.001

 Procedure

0 (0–0)

0 (0–0)

0 (0–0)

0.274

 Drug

0 (0–0)

14 (5–55)

0 (0–0)

<  0.001

 Prescribed nutrition

0 (0–0)

0 (0–0)

0 (0–0)

0.003

Direct non-medical

3 (2–4)

4 (2–5)

3 (2–4)

<  0.001

 Travel to attend health facility

3 (2–4)

4 (2–5)

3 (2–3)

0.002

 Food purchased to attend health facility

0 (0–0)

0 (0–0)

0 (0–0)

0.854

 Accommodation to attend health facility

0 (0–0)

0 (0–0)

0 (0–0)

0.274

 DOT costs (travel)

0 (0–0)

0 (0–0)

0 (0–0)

0.935

Indirect

6 (3–13)

20 (3–76)

4 (3–10)

<  0.001

 Loss of wages to attend health facility

3 (0–6)

8 (0–21)

3 (0–6)

0.029

 Wage loss of accompanying member

0 (0–3)

0 (0–19)

0 (0–3)

0.84

 Household income loss due to TB

0 (0–0)

0 (0–27)

0 (0–0)

0.003

Total costs

8 (5–28)

61 (35–156)

7 (5–14)

<  0.001

  1. IQR Inter-quartile Range; DOT Directly Observed Treatment; USD 1 = INR 70